Press release
Mesothelioma Pipeline Dynamics 2024: FDA Approvals, Therapeutic Advances, by DelveInsight | GSK, Merck, Bristol-Myers Squibb, AstraZeneca, Roche, Novartis, Pfizer Inc., Eli Lilly and Company, J&J
"Mesothelioma Pipeline Insight, 2024 [https://www.delveinsight.com/sample-request/mesothelioma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Mesothelioma Market.
The Mesothelioma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Mesothelioma Pipeline Report:
*
Companies across the globe are diligently working toward developing novel Mesothelioma treatment therapies with a considerable amount of success over the years.
*
Mesothelioma companies working in the treatment market are The Netherlands Cancer Institute, Bristol-Myers Squibb, PrECOG, LLC., Memorial Sloan Kettering Cancer Center, ETOP IBCSG Partners Foundation, MedImmune LLC, Aslaug Helland, AstraZeneca, Oncotelic Inc., Hyogo Medical University, Trizell Ltd, RS Oncology LLC, Vivace Therapeutics, Inc, TCR2 Therapeutics, Sanofi, ImmVira Pharma Co. Ltd, TCR2 Therapeutics, CRISPR Therapeutics, Biotheus Inc., and others, are developing therapies for the Mesothelioma treatment
*
Emerging Mesothelioma therapies in the different phases of clinical trials are- Pembrolizumab, Nivolumab, Durvalumab, Sacituzumab govitecan-hziy, Carboplatin, Tremelimumab, ipilimumab, Volrustomig, OT-101, Lenvatinib, rAd-IFN, RSO-021, VT3989, gavo-cel, THOR-707, T3011, TC-510, CTX131, PM8002, and others are expected to have a significant impact on the Mesothelioma market in the coming years.
*
In March 2024, Ultimovacs, a clinical-stage biotechnology company, has released data from the Phase II NIPU trial of its UV1 cancer vaccine. This investigator-initiated, open-label, multi-center Phase II trial evaluated the impact of incorporating the UV1 cancer vaccine into second-line treatment with ipilimumab and nivolumab for patients with pleural mesothelioma.
*
In December 2023, Sellas Life Sciences, a US-based late-stage clinical biopharmaceutical company, announced that its Phase I study (NCT02737787) of galinpepimut-S combined with Opdivo (nivolumab) has successfully met its primary endpoint, showing improved overall survival in mesothelioma patients.
Mesothelioma Overview
Mesothelioma is a type of cancer that develops from the thin layer of tissue that covers many of the internal organs (mesothelium). The most common form is pleural mesothelioma, which affects the lining of the lungs and is often associated with exposure to asbestos fibers. Other less common forms include peritoneal mesothelioma (affecting the lining of the abdomen), pericardial mesothelioma (affecting the lining around the heart), and mesothelioma of the tunica vaginalis (affecting the lining of the testes).
Get a Free Sample PDF Report to know more about Mesothelioma Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/mesothelioma-pipeline-insight [https://www.delveinsight.com/report-store/mesothelioma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Emerging Mesothelioma Drugs Under Different Phases of Clinical Development Include:
*
Pembrolizumab: The Netherlands Cancer Institute
*
Nivolumab: Bristol-Myers Squibb
*
Durvalumab: PrECOG, LLC.
*
Sacituzumab govitecan-hziy: Memorial Sloan Kettering Cancer Center
*
Carboplatin: ETOP IBCSG Partners Foundation
*
Tremelimumab: MedImmune LLC
*
ipilimumab: Aslaug Helland
*
Volrustomig: AstraZeneca
*
OT-101: Oncotelic Inc.
*
Lenvatinib: Hyogo Medical University
*
rAd-IFN: Trizell Ltd
*
RSO-021: RS Oncology LLC
*
VT3989: Vivace Therapeutics, Inc
*
gavo-cel: TCR2 Therapeutics
*
THOR-707: Sanofi
*
T3011: ImmVira Pharma Co. Ltd
*
TC-510: TCR2 Therapeutics
*
CTX131: CRISPR Therapeutics
*
PM8002: Biotheus Inc.
Mesothelioma Route of Administration
Mesothelioma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
*
Oral
*
Parenteral
*
Intravenous
*
Subcutaneous
*
Topical
Mesothelioma Molecule Type
Mesothelioma Products have been categorized under various Molecule types, such as
*
Recombinant fusion proteins
*
Small molecule
*
Monoclonal antibody
*
Peptide
*
Polymer
*
Gene therapy
Mesothelioma Pipeline Therapeutics Assessment
*
Mesothelioma Assessment by Product Type
*
Mesothelioma By Stage and Product Type
*
Mesothelioma Assessment by Route of Administration
*
Mesothelioma By Stage and Route of Administration
*
Mesothelioma Assessment by Molecule Type
*
Mesothelioma by Stage and Molecule Type
DelveInsight's Mesothelioma Report covers around 50+ products under different phases of clinical development like
*
Late-stage products (Phase III)
*
Mid-stage products (Phase II)
*
Early-stage product (Phase I)
*
Pre-clinical and Discovery stage candidates
*
Discontinued & Inactive candidates
*
Route of Administration
Further Mesothelioma product details are provided in the report. Download the Mesothelioma pipeline report to learn more about the emerging Mesothelioma therapies [https://www.delveinsight.com/sample-request/mesothelioma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Some of the key companies in the Mesothelioma Therapeutics Market include:
Key companies developing therapies for Mesothelioma are - Merck & Co., Inc., Bristol-Myers Squibb, AstraZeneca, Roche, Novartis, Pfizer Inc., Eli Lilly and Company, Johnson & Johnson, GlaxoSmithKline plc (GSK), AbbVie Inc., Sanofi, and others.
Mesothelioma Pipeline Analysis:
*
The Mesothelioma pipeline report provides insights into
*
The report provides detailed insights about companies that are developing therapies for the treatment of Mesothelioma with aggregate therapies developed by each company for the same.
*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Mesothelioma Treatment.
*
Mesothelioma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
*
Mesothelioma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Mesothelioma market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Mesothelioma drugs and therapies [https://www.delveinsight.com/sample-request/mesothelioma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Mesothelioma Pipeline Market Drivers
*
Advancements in Treatment, Targeted Therapies, Immunotherapy Innovations, Early Diagnosis Initiatives, Increased Awareness, are some of the important factors that are fueling the Mesothelioma Market.
Mesothelioma Pipeline Market Barriers
*
However, Limited Treatment Option, Diagnostic Challenges, High Development Costs, Patient Heterogeneity, Lack of Funding, and other factors are creating obstacles in the Mesothelioma Market growth.
Scope of Mesothelioma Pipeline Drug Insight
*
Coverage: Global
*
Key Mesothelioma Companies: The Netherlands Cancer Institute, Bristol-Myers Squibb, PrECOG, LLC., Memorial Sloan Kettering Cancer Center, ETOP IBCSG Partners Foundation, MedImmune LLC, Aslaug Helland, AstraZeneca, Oncotelic Inc., Hyogo Medical University, Trizell Ltd, RS Oncology LLC, Vivace Therapeutics, Inc, TCR2 Therapeutics, Sanofi, ImmVira Pharma Co. Ltd, TCR2 Therapeutics, CRISPR Therapeutics, Biotheus Inc., and others
*
Key Mesothelioma Therapies: Pembrolizumab, Nivolumab, Durvalumab, Sacituzumab govitecan-hziy, Carboplatin, Tremelimumab, ipilimumab, Volrustomig, OT-101, Lenvatinib, rAd-IFN, RSO-021, VT3989, gavo-cel, THOR-707, T3011, TC-510, CTX131, PM8002, and others
*
Mesothelioma Therapeutic Assessment: Mesothelioma current marketed and Mesothelioma emerging therapies
*
Mesothelioma Market Dynamics: Mesothelioma market drivers and Mesothelioma market barriers
Request for Sample PDF Report for Mesothelioma Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/mesothelioma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Table of Contents
1. Mesothelioma Report Introduction
2. Mesothelioma Executive Summary
3. Mesothelioma Overview
4. Mesothelioma- Analytical Perspective In-depth Commercial Assessment
5. Mesothelioma Pipeline Therapeutics
6. Mesothelioma Late Stage Products (Phase II/III)
7. Mesothelioma Mid Stage Products (Phase II)
8. Mesothelioma Early Stage Products (Phase I)
9. Mesothelioma Preclinical Stage Products
10. Mesothelioma Therapeutics Assessment
11. Mesothelioma Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Mesothelioma Key Companies
14. Mesothelioma Key Products
15. Mesothelioma Unmet Needs
16 . Mesothelioma Market Drivers and Barriers
17. Mesothelioma Future Perspectives and Conclusion
18. Mesothelioma Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=mesothelioma-pipeline-dynamics-2024-fda-approvals-therapeutic-advances-by-delveinsight-gsk-merck-bristolmyers-squibb-astrazeneca-roche-novartis-pfizer-inc-eli-lilly-and-company-jj]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Mesothelioma Pipeline Dynamics 2024: FDA Approvals, Therapeutic Advances, by DelveInsight | GSK, Merck, Bristol-Myers Squibb, AstraZeneca, Roche, Novartis, Pfizer Inc., Eli Lilly and Company, J&J here
News-ID: 3606220 • Views: …
More Releases from ABNewswire
Hillman Unveils New-Generation Hunting Boots for Men Featuring Dual-Insulation a …
Image: https://www.abnewswire.com/upload/2025/09/ba5edccf338bc4d7305201efbc60a77a.jpg
Hillman, the performance hunting brand trusted by professionals across rugged North American terrain, today announced the release of its next-generation line of hunting boots for men [https://hillmangear.com/collections/hunting-boots-men-s-hunt-footwear], engineered with a dual-insulation system inspired by space technology. The new hunting boots collection features NASA-developed Aerogel Trademark paired with Matrix Registered insulation to deliver arctic-level warmth at a fraction of the weight and bulk of traditional padded boots.
Purpose-built for early season…
Cedric D. Fisher & Company Publishers Releases SIGHT: Groundbreaking Novel Explo …
Cedric D. Fisher & Company Publishers launches SIGHT by Alexandria Clarimond, a literary fiction novel following Elora ("Ellie") through seven decades of life as she confronts progressive blindness from macular degeneration. The novel's innovative "Seven Sight Loss Events" structure parallels physical vision decline with spiritual awakening, creating a powerful meditation on resilience and meaning.
SAN ANTONIO, TX - September 18th, 2025 - Cedric D. Fisher & Company Publishers, a San Antonio-based…
New Launch Protech Systems - A Security System Installation Company in Vancouver …
Protech Systems, a newly launched security system installation company in Vancouver, BC, is now open to serve homeowners and businesses. The company specializes in installing and integrating advanced security solutions, including alarm systems, security cameras, smart home integrations, and monitoring services.
Vancouver, BC - Protech Systems has officially launched in Vancouver, British Columbia, bringing modern home and commercial security solutions to families and business owners across the Lower Mainland. With over…
Soft Tissue Sarcoma Market to Experience Notable Growth in Forecast Span by 2034 …
The Key Soft Tissue Sarcoma Companies in the market include - Epizyme, Blueprint Medicines, Eli Lilly, Philogen, Intensity Therapeutics, Peel Therapeutics, Pure Biologics, Edgewood Oncology, Advenchen Laboratories, Philogen, Gradalis, Epizyme, Chugai Pharma France, CytRx, Taiho Pharmaceuticals, KaryoPharm Therapeutics, Nanobiotix, Apexigen, Lytix Biopharma, Incyte Corporation, Iovance Biotherapeutics, Aadi Bioscience, and others.
The Soft Tissue Sarcoma market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period.…
More Releases for Mesothelioma
Mesothelioma Pipeline Outlook Report 2024 (Updated)
DelveInsight's, "Mesothelioma Pipeline Insight 2024" report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in Mesothelioma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Mesothelioma Pipeline Report
• DelveInsight's Mesothelioma pipeline report depicts a…
Mesothelioma Resource Centre Introduced the All Legal Rights and Options Platfor …
Mesothelioma Resource Centre announced the platform for all legal rights and options of Asbestos & Mesothelioma. It is the legal and health resources center for all sufferers of mesothelioma cancer, a cancer almost always caused by exposure to asbestos.
Generally, a mesothelioma victim must immediately seek redress once diagnosed with the cancer because if the disease has been established to be work-related and the responsible company is identified, a mesothelioma…
New Mesothelioma Treatment Technique Developed
Extrapleural pneumonectomy, a surgical procedure that removes mesothelioma cancer from the lining of the lung, has been reported to be an effective new mesothelioma treatment technique. The technique was developed by Dr. Sugarbaker, the co-leader of the Brigham Biomedical Research Institute's Cancer Research Center, Chief of the Institute's Division of Thoracic Surgery and a Professor of Oncologic Surgery at Harvard Medical School.
The surgical technique was applied on a mesothelioma patient…
Mesothelioma Cancer: Possible Treatment Option
An experiment carried out in Memorial Sloan-Kettering Cancer Center, Mount Sinai School of Medicine and the Medical University Vienna has tested the effectiveness of a genetically modified virus to treat mesothelioma in animals. The virus is known as Newcastle Disease Virus (NDV). Animals with mesothelioma administered with multiple doses of NDV responded better than those that received a single dose.
The use of a genetically engineered virus to disrupt the function…
Veteran Passed Away from Mesothelioma Cancer
It has been reported that a U.S. Army veteran passed away at the age of 64 from the asbestos cancer, malignant mesothelioma. He retired from the U.S. Army Corps of Engineers after 25 years of service. Prior to his military career, he worked at a steel company. It is likely that his mesothelioma was caused by asbestos exposure that he encountered at the steel company and during military service.
Malignant mesothelioma…
Weitz & Luxenberg Mesothelioma Lawyers win $1.28 Million Settlement in Mesotheli …
Weitz & Luxenberg mesothelioma lawyers recently secured a $1.28 million settlement for a 77-year-old former carpenter suffering from the asbestos cancer, mesothelioma. Prior to this settlement, Weitz & Luxenberg obtained $842,000 from another defendant.
The former carpenter is the father of six children and devoted his 30-year career to beautifying such New York City landmarks as Yankee Stadium and the Empire State Building. He was diagnosed with mesothelioma in…
